Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 387

The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.

Ceramides and other sphingolipids as drivers of cardiovascular disease

Open access
Choi, Ran Hee, Tatum, Sean M., Symons, J. David, Summers, Scott A., Holland, William L.·2021·Nature Reviews Cardiology

Abstract

Increases in calorie consumption and sedentary lifestyles are fuelling a global pandemic of cardiometabolic diseases, including coronary artery disease, diabetes mellitus, cardiomyopathy and heart failure. These lifestyle factors, when combined with genetic predispositions, increase the levels of circulating lipids, which can accumulate in non-adipose tissues, including blood vessel walls and the heart. The metabolism of these lipids produces bioactive intermediates that disrupt cellular function and survival. A compelling body of evidence suggests that sphingolipids, such as ceramides, account for much of the tissue damage in these cardiometabolic diseases. In humans, serum ceramide levels are proving to be accurate biomarkers of adverse cardiovascular disease outcomes. In mice and rats, pharmacological inhibition or depletion of enzymes driving de novo ceramide synthesis prevents the development of diabetes, atherosclerosis, hypertension and heart failure. In cultured cells and isolated tissues, ceramides perturb mitochondrial function, block fuel usage, disrupt vasodilatation and promote apoptosis. In this Review, we discuss the body of literature suggesting that ceramides are drivers — and not merely passengers — on the road to cardiovascular disease. Moreover, we explore the feasibility of therapeutic strategies to lower ceramide levels to improve cardiovascular health. The metabolism of lipids accumulated in blood vessel walls and the heart produces sphingolipids, such as ceramides, which are associated with the development of diabetes mellitus, atherosclerosis, hypertension and heart failure. In this Review, the authors discuss ceramides as drivers of cardiovascular disease and therapeutic strategies to lower plasma and cardiac levels of ceramides. Ceramides have been shown to accumulate in many tissues, including blood vessels and the heart, in individuals with cardiovascular disease (such as hypertension, heart failure and atherosclerosis). Serum ceramide levels are measured clinically as prognostic indicators of major adverse cardiovascular events. Inhibiting ceramide biosynthesis in mice and rats prevents the development of hypertension, atherosclerosis, diabetes mellitus and heart failure. Ceramides have pleiotropic actions that are relevant to metabolic disease, including inhibiting nitric oxide synthase, decreasing insulin sensitivity, altering mitochondrial bioenergetics, and inducing apoptosis and fibrosis. Several enzymes that control ceramide production or metabolism have emerged as attractive therapeutic targets for treating a wide range of cardiometabolic pathologies. Ceramides have been shown to accumulate in many tissues, including blood vessels and the heart, in individuals with cardiovascular disease (such as hypertension, heart failure and atherosclerosis). Serum ceramide levels are measured clinically as prognostic indicators of major adverse cardiovascular events. Inhibiting ceramide biosynthesis in mice and rats prevents the development of hypertension, atherosclerosis, diabetes mellitus and heart failure. Ceramides have pleiotropic actions that are relevant to metabolic disease, including inhibiting nitric oxide synthase, decreasing insulin sensitivity, altering mitochondrial bioenergetics, and inducing apoptosis and fibrosis. Several enzymes that control ceramide production or metabolism have emerged as attractive therapeutic targets for treating a wide range of cardiometabolic pathologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-021-00536-1

Cites

171 of 171 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 171 references

Cited by

See all 387

Metadata

Authors
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L.
Venue
Nature Reviews Cardiology
Published
2021-03-26
Volume
18
Issue
10
Pages
701-711
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W3136668199
Cited by
387
References
171
FWCI
5.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ceramides and other sphingolipids as drivers of cardiovascular disease. https://app.cochat.ai/papers/10.1038/s41569-021-00536-1
The paper
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L. (2021). Ceramides and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-021-00536-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.